Year Year arrow
arrow-active-down-0
Publisher Publisher arrow
arrow-active-down-1
Journal
1
Journal arrow
arrow-active-down-2
Institution Institution arrow
arrow-active-down-3
Institution Country Institution Country arrow
arrow-active-down-4
Publication Type Publication Type arrow
arrow-active-down-5
Field Of Study Field Of Study arrow
arrow-active-down-6
Topics Topics arrow
arrow-active-down-7
Open Access Open Access arrow
arrow-active-down-8
Language Language arrow
arrow-active-down-9
Filter Icon Filter 1
Year Year arrow
arrow-active-down-0
Publisher Publisher arrow
arrow-active-down-1
Journal
1
Journal arrow
arrow-active-down-2
Institution Institution arrow
arrow-active-down-3
Institution Country Institution Country arrow
arrow-active-down-4
Publication Type Publication Type arrow
arrow-active-down-5
Field Of Study Field Of Study arrow
arrow-active-down-6
Topics Topics arrow
arrow-active-down-7
Open Access Open Access arrow
arrow-active-down-8
Language Language arrow
arrow-active-down-9
Filter Icon Filter 1
Export
Sort by: Relevance
  • Research Article
  • Cite Count Icon 2
  • 10.1038/s41574-024-01043-2
Brown adipose tissue fights the battle against leukaemia
  • Sep 20, 2024
  • Nature Reviews Endocrinology
  • Pamela Fischer-Posovszky + 1 more

  • Research Article
  • Cite Count Icon 9
  • 10.1038/s41574-024-01041-4
Skeletal muscle loss and sarcopenia in obesity pharmacotherapy
  • Sep 18, 2024
  • Nature Reviews Endocrinology
  • David C D Hope + 1 more

  • Open Access Icon
  • Discussion
  • Cite Count Icon 2
  • 10.1038/s41574-024-00975-z
Slowly progressive insulin-dependent diabetes mellitus in type 1 diabetes endotype 2.
  • Mar 21, 2024
  • Nature Reviews Endocrinology
  • Tetsuro Kobayashi + 1 more

  • Research Article
  • Cite Count Icon 2
  • 10.1038/s41574-024-00982-0
Sex differences in diabetic kidney disease explained.
  • Mar 20, 2024
  • Nature Reviews Endocrinology
  • Claire Greenhill

  • Open Access Icon
  • Discussion
  • 10.1038/s41574-024-00978-w
Reply to 'Tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern'.
  • Mar 20, 2024
  • Nature Reviews Endocrinology
  • Stephan Petersenn + 2 more

  • Open Access Icon
  • Discussion
  • Cite Count Icon 6
  • 10.1038/s41574-024-00976-y
Tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern.
  • Mar 20, 2024
  • Nature Reviews Endocrinology
  • Sunita M C De Sousa + 7 more

  • Research Article
  • Cite Count Icon 5
  • 10.1038/s41574-024-00972-2
Thyroid-function reference ranges in the diagnosis of thyroid dysfunction in adults.
  • Mar 8, 2024
  • Nature Reviews Endocrinology
  • Salman Razvi

  • Research Article
  • Cite Count Icon 22
  • 10.1038/s41574-024-00958-0
Endocrine disrupting chemicals are a threat to hormone health: a commentary on behalf of the ESE.
  • Feb 22, 2024
  • Nature Reviews Endocrinology
  • Martin Reincke + 4 more

  • Research Article
  • 10.1038/s41574-024-00964-2
FGF21 suppresses CD8+ T cell antitumour activity.
  • Feb 20, 2024
  • Nature Reviews Endocrinology
  • Olivia Tysoe

  • Open Access Icon
  • Research Article
  • Cite Count Icon 19
  • 10.1038/s41574-023-00948-8
Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part1, general recommendations.
  • Feb 9, 2024
  • Nature Reviews Endocrinology
  • Márta Korbonits + 16 more

Tumours of the anterior part of the pituitary gland represent just 1% of all childhood (aged <15 years) intracranial neoplasms, yet they can confer high morbidity and little evidence and guidance is in place for their management. Between 2014 and 2022, a multidisciplinary expert group systematically developed the first comprehensive clinical practice consensus guideline for children and young people under the age 19 years (hereafter referred to as CYP) presenting with a suspected pituitary adenoma to inform specialist care and improve health outcomes. Through robust literature searches and a Delphi consensus exercise with an international Delphi consensus panel of experts, the available scientific evidence and expert opinions were consolidated into 74 recommendations. Part 1 of this consensus guideline includes 17 pragmatic management recommendations related to clinical care, neuroimaging, visual assessment, histopathology, genetics, pituitary surgery and radiotherapy. While in many aspects the care for CYP is similar to that of adults, key differences exist, particularly in aetiology and presentation. CYP with suspected pituitary adenomas require careful clinical examination, appropriate hormonal work-up, dedicated pituitary imaging and visual assessment. Consideration should be given to the potential for syndromic disease and genetic assessment. Multidisciplinary discussion at both the local and national levels can be key for management. Surgery should be performed in specialist centres. The collection of outcome data on novel modalities of medical treatment, surgical intervention and radiotherapy is essential for optimal future treatment.